Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2

Growth Factor ◽

Growth Factor Receptor ◽

Efficacy And Safety ◽

Post Hoc Analysis ◽

Epidermal Growth ◽

Post Hoc

Abstract PS10-14: Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2

10.1158/1538-7445.sabcs20-ps10-14 ◽

2021 ◽

Author(s):

Karen Gelmon ◽

Janice M Walshe ◽

Reshma Mahtani ◽

Anil A Joy ◽

Meghan Karuturi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Efficacy And Safety ◽

Post Hoc Analysis ◽

Epidermal Growth ◽

Post Hoc

Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdx365.011 ◽

2017 ◽

Vol 28 ◽

pp. v79-v80

Author(s):

R.S. Finn ◽

K.A. Gelmon ◽

J. Ettl ◽

J. Asselah ◽

A. Castrellon ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Efficacy And Safety ◽

First Line ◽

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Molecular Medicine Reports ◽

10.3892/mmr.2018.8580 ◽

2018 ◽

Cited By ~ 1

Author(s):

Seung Taek Lim ◽

Ye Won Jeon ◽

Hongki Gwak ◽

Se Young Kim ◽

Young Jin Suh

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Breast Cancer Cells ◽

Growth Factor Receptor ◽

Anticancer Effects ◽

Epidermal Growth ◽

Positive Breast Cancer

Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

10.1158/1538-7445.sabcs18-ot1-03-01 ◽

2019 ◽

Author(s):

G Curigliano ◽

S Cresta ◽

Y-S Yap ◽

D Juric ◽

FP Duhoux ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

10.1158/1538-7445.sabcs19-pd7-07 ◽

2020 ◽

Author(s):

Virginia Kaklamani ◽

Aditya Bardia ◽

Sharon Wilks ◽

Amy Weise ◽

Donald Richards ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Final Analysis ◽

Phase 1 Study ◽

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer

Cancer Science ◽

10.1111/cas.12897 ◽

2016 ◽

Vol 107 (4) ◽

pp. 491-498 ◽

Cited By ~ 19

Author(s):

Mai Tomiguchi ◽

Yutaka Yamamoto ◽

Mutsuko Yamamoto‐Ibusuki ◽

Lisa Goto‐Yamaguchi ◽

Yoshitaka Fujiki ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Fibroblast Growth Factor Receptor ◽

Growth Factor Receptor ◽

Fibroblast Growth ◽

Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factor

Molecular and Clinical Oncology ◽

10.3892/mco.2016.776 ◽

2016 ◽

Vol 4 (4) ◽

pp. 648-654 ◽

Cited By ~ 11

Author(s):

MASAHIRO OHARA ◽

KAZUO MATSUURA ◽

ETSUSHI AKIMOTO ◽

MIDORI NOMA ◽

MIHOKO DOI ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Prognostic Value ◽

Growth Factor Receptor ◽

Ki67 Labeling Index ◽

PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L)

Annals of Oncology ◽

10.1093/annonc/mdx365.054 ◽

2017 ◽

Vol 28 ◽

pp. v96 ◽

Cited By ~ 3

Author(s):

V. Diéras ◽

N. Harbeck ◽

A.A. Joy ◽

K.A. Gelmon ◽

J. Ettl ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Growth Factor Receptor ◽

First Line ◽

Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs17-p1-10-07 ◽

2018 ◽

Author(s):

M Campone ◽

J Sachdev ◽

GV Bianchi ◽

JT Beck ◽

N Martínez-Jáñez ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Randomized Phase Ii ◽

Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer

10.1158/1538-7445.sabcs19-p5-11-02 ◽

2020 ◽

Author(s):

Mario Campone ◽

Aditya Bardia ◽

Gary A Ulaner ◽

Sarat Chandarlapaty ◽

Alice Gosselin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Dose Escalation Study ◽